器官・組織的移植以及替代技術產品市場 是由出版商BCC Research在2011年01月所出版的。
這份英文市場調查報告書包含233 Pages 價格從美金4850起跳。
全球的移植產品、裝置、醫藥品市場在2010年達將近540億美元。今後預期將以CAGR8.3%擴大，至2015年將達800億美元。
本報告，以器官・組織別詳細調查分析器官移植・組織移植以及替代技術產品市場，彙整業界概要、移植程序、各種法規、移植相關產品・醫藥品的種類別市場實績・預測（∼2015）、各種移植手術・替代方法、主要企業的檔案資料等，由下列摘要形式闡述。
第1章 簡介
第2章 摘要
第3章 業界概要
- 移植的歷史
- 器官・組織移植的必要元件
- 捐贈程序概要
- 移植程序
- 實體器官
- 美國的組織移植
- 美國以外的移植動向
- 供給限制阻移植
- 業界成長促進因子
- 業界成長阻礙因子
第4章 組織型決定技術
- 群組反應性抗體
- 組織型決定技術
- 全球的組織型決定市場
第5章 實體器官的取得與保存
- 腦死的定義
- 接受移植的器官
- 美國的供給增加
- 移植的擴大與管理
- 供給管理
- 美國以外的器官取得
- 美國的分配基準
- EU的分配基準
- 實體器官的保存
- 保存液市場
- 機器灌注
第6章 組織產品
- 組織產品的地區別擴大
- 軟組織同種異體移植市場
- 組織市場的機會
- 心臟瓣膜
- 角膜
- 血液幹細胞
- 臍帶血
- 骨生物活性材料市場
- 皮膚・膠原蛋白移植
- 美國的血管組織移植
- 組織移植的商業機會
第7章 免疫抑制劑
- 移植器官的忍受性
- 一般的抗排斥藥物協議
- 免疫抑制劑的種類 其他
第8章 器官・組織移植的抗感染・移植後監控
- 抗感染藥物與免疫抑制劑
- 移植後監控
- 術後監控的市場機會
第9章 替代裝置與技術
- 角膜移植
- 小腸移植
- 肝臟移植
- 肺移植
- 骨頭移植
- 血管移植
- 皮膚移植
- 心臟移植
- 整形外科裝置
第10章 法律規範與醫療報銷
- 美國的法律規範
- 美國以外的法律規範
- 美國的醫療報銷
- 美國以外的醫療報銷
第11章 開發中的新興處置與產品
- 實體器官的機器灌注
- 開發中的組織保存液
- 再生醫療
- 器官排斥對策
- 幹細胞研究
- 心血管治療的進歩
- 醫藥品產品線開發
第12章 企業名錄
第13章 附錄
Abstract
REPORT HIGHLIGHTS
- The global market for transplantation products, devices, and
pharmaceuticals was valued at nearly $54 billion in 2010 and is projected to
grow at an 8.3% compound annual growth rate (CAGR) to reach $80 billion in
2015.
- BCC projects that the fastest growing areas of the transplantation market
are in tissue typing and tissue products. Tissue typing technologies are
expected to grow at a compound annual growth rate (CAGR) of 12% through the
forecast period, from a value of $313 million in 2010 to $553 million in 2015.
Tissue product development should grow at a CAGR of 10.8%, from 15.6 billion
in 2010 to more than $26 billion by 2015.
- Alternatives to organ and tissue transplantation continue to add options
for cardiac and orthopedic patients, among others. The alternative
technologies sector was valued at nearly $29 billion in 2010 and is expected
to increase at a 6.9% compound annual growth rate (CAGR) to reach $40 billion
in 2015.
REPORT SCOPEINTRODUCTION
REASONS FOR DOING THE STUDY
The objective of this study is to provide an in-depth analysis and forecast of
the solid organ and tissue transplantation markets. The focus is on products
and procedures used or under development for organ and tissue
transplantations, including techniques, therapies, drugs, and diagnostics.
Additionally, a market analysis of alternative transplantations with devices
such as ventricular assist devices (VAD), total artificial hearts (TAH), and
orthopedic replacement and reconstruction devices will be explored.
STUDY GOALS AND OBJECTIVES
Organ transplantation is a dynamic field, with continuing progress in the
development of artificial organs and transplantation methods that reduce
rejection and infection. There are increased pressures to ensure
transplantation methods are as efficient and effective as possible because the
need for organ donors far outstrips the availability of organs and tissues
In theory, transplantation is the last therapeutic option available to people
in the final stage of an organ or tissue failure. In reality, the supply of
organs or tissues is so limited that for the vast majority of people,
transplantation is not an option. Despite the lack of organs, the
transplantation business continues to innovate through better harvesting and
procurement techniques, vastly improved immunosuppression regimens, advanced
tissue matching, and effective anti-infective regimens, all of which have
helped build the organ and tissue transplantation business to a maturing stage.
This report will focus on procurement and preservation, solid organ
transplantation, tissue transplantation, immunosuppressives and other
pharmaceuticals, post-transplantation concerns, and alternatives to
transplantation. Although the organ transplantation business faces tough
challenges, it also offers exciting fields of research and tremendous
opportunities to meet growing market demand.
With transplant recipients living much longer, there is a growing need for
post-transplant immunosuppression and monitoring. This aspect of the
transplantation process will be covered, describing post-transplant drug
regimens and patient and graft survival rates.
This report is a valuable tool for anyone assessing the organ and tissue
transplantation market and attempting to devise a strategy to successfully
compete in this market. This report provides a thorough background on the
structure of the organ and tissue transplantation market and the chief
challenges and opportunities it faces. It offers the information needed to
understand the current market and to address the emerging one.
This is an invaluable tool for business planners, acquisitions specialists,
licensing strategists, product managers, market research analysts, investing
consultants, and others interested in the tissue and transplantation market,
its products, its participants, and its future.
SCOPE OF REPORT
This report offers forecasts, by product segment, from 2010 through 2015,
including supporting analyses for projections. Product segments covered
consist of solid organ (e.g., kidneys, liver, heart-lung, pancreas,
intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart
valves) markets, along with the pharmaceuticals that accompany each market.
Also included are experimental xenografts and artificial organs; tissue
transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral
blood, islet cell). The report touches on the use of fetal cells, stem cells,
and altered cancer cells.
The arrangement of this report offers an overview of the key elements in the
transplantation process: tissue typing, procurement and preservation,
immunosuppressants for solid organ and tissue transplants, and postoperative
monitoring. International markets are discussed, and information is provided
on industry structure and the regulatory environment.
Within each section are discussions of commercialization opportunities for
each segment of the market. New or emerging devices, techniques, and
pharmaceuticals are highlighted.
Profiles of more than 50 leading companies involved with solid organ
transplantation, tissue transplantation, and alternative technologies are
included. The report provides information on company placement within the
market and strategic analyses of the companies' available and emerging
products.
An appendix featuring various terms and processes used in transplantation is
provided at the end of the report.
This report cites autologous products only in relation to their impact on the
market for allografts. It does not include blood products, with the exception
of peripheral and umbilical cord blood as a source of stem cells.
METHODOLOGIES AND INFORMATION SOURCES
Information for this report was derived from a variety of primary and
secondary research sources, including industry analysts, annual reports and
Securities and Exchange Commission (SEC) reports, the United Network for Organ
Sharing (UNOS), the Organ Procurement and Transplantation Network (OPTN), the
Scientific Registry of Transplant Recipients (SRTR), the Center for Medicare
and Medicaid Services (CMS), the National Institutes of Health (NIH), the
Centers for Disease Control (CDC), other government agencies, and journal
articles. Secondary sources include literature searches; product literature;
and press releases.
When precise information was not available, a consensus was made using
reasonable assumptions and estimates based on historical data.
ANALYST CREDENTIALS
Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr has worked
with the publishing arms of for-profit and not-for-profit organizations for
more than 25 years, and she specializes in marketing reports on the medical
industry. She has contributed several reports on the medical industry for BCC,
including reports on the global market for catheters, the sterilization
market, reports on pediatric and eldercare markets, and her most recent report
on the cardiovascular surgical industry.
Table of Contents
Chapter- 1: INTRODUCTION - Complimentary
- REASONS FOR DOING THE STUDY
- STUDY GOALS AND OBJECTIVES
- SCOPE OF REPORT
- METHODOLOGIES AND INFORMATION SOURCES
- ANALYST CREDENTIALS
- RELATED BCC REPORTS
- BCC ONLINE SERVICES
- DISCLAIMER
Chapter- 2: SUMMARY
- Table 0 : PROJECTED GLOBAL MARKET FOR TRANSPLANTATION PRODUCTS AND
DEVICES, THROUGH 2015
- Figure 0 : PROJECTED GLOBAL MARKET SHARES OF TRANSPLANTATION PRODUCTS AND
DEVICES, 2010 AND 2015
Chapter- 3: INDUSTRY OVERVIEW
- HISTORY OF TRANSPLANTATION
- INDUSTRY ACQUISITIONS
- NECESSARY COMPONENTS TO ORGAN AND TISSUE TRANSPLANTATION
- OVERVIEW OF THE DONATION PROCESS
- THE TRANSPLANTATION PROCESS
- SOLID ORGANS
- TISSUE TRANSPLANTATION IN THE U.S.
- TRANSPLANTATION TRENDS OUTSIDE THE U.S.
- LIMITED SUPPLY CURTAILS TRANSPLANTATIONS
- KEY FACTORS IN INDUSTRY GROWTH
- KEY FACTORS INHIBITING GROWTH
Chapter- 4: TISSUE TYPING TECHOLOGIES
- PANEL REACTIVE ANTIBODIES
- TISSUE TYPING TECHNOLOGIES
- GLOBAL TISSUE TYPING MARKET
- Table 8 : PROJECTED GLOBAL MARKET FOR TISSUE TYPING, THROUGH 2015
Chapter- 5: SOLID ORGAN PROCUREMENT AND PRESERVATION
- DEFINITION OF BRAIN DEATH
- ORGANS OBTAINED FOR TRANSPLANT
- INCREASING SUPPLY IN THE U.S.
- THE TRANSPLANT GROWTH AND MANAGEMENT COLLABORATIVE
- SUPPLY MANAGEMENT
- ORGAN PROCUREMENT OUTSIDE THE U.S.
- ALLOCATION CRITERIA IN THE U.S.
- ALLOCATION CRITERIA IN THE EU
- SOLID ORGAN PRESERVATION
- MARKET FOR PRESERVATION SOLUTIONS
- MACHINE PERFUSION
Chapter- 6: TISSUE PRODUCTS
- REGIONAL GROWTH IN TISSUE PRODUCTS
- SOFT TISSUE ALLOGRAFT MARKET
- OPPORTUNITIES IN THE TISSUE MARKET
- HEART VALVES
- CORNEA
- BLOOD STEM CELLS
- CORD BLOOD
- THE ORTHOBIOLOGICS MARKET
- SKIN AND COLLAGEN TRANSPLANTS
- VASCULAR TISSUE TRANSPLANTATION IN THE U.S.
- COMMERCIAL OPPORTUNITIES IN TISSUE TRANSPLANTATION
- Table 25 : SELECTED COMMERCIAL OPPORTUNITIES IN TISSUE TRANSPLANTATION,
2010
Chapter- 7: IMMUNOSUPPRESSANTS
- TOLERANCE OF TRANSPLANTED ORGANS
- USUAL ANTI-REJECTION DRUG PROTOCOLS
- TYPES OF IMMUNOSUPPRESSANTS
- CALCINEURIN INHIBITORS
- ANTI-PROLIFERATIVE AGENTS
- M-TOR INHIBITORS
- MONOCLONAL, POLYCLONAL ANTIBODIES
- TREATMENTS BY STAGE OF PROCEDURE
- MAINTENANCE THERAPY
- IMMUNOSUPPRESSANT USE IN REJECTION THERAPY
- MARKET POSSIBILITIES FOR FUTURE TRANSPLANTATION DRUGS
- IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT
- Table 38 : SELECTED IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT, 2010
Chapter- 8: ANTI-INFECTIVES AND POST-TRANSPLANT MONITORING IN ORGAN AND TISSUE TRANSPLANTATION
- ANTI-INFECTIVES AND IMMUNOSUPPRESSANTS
- POST-TRANSPLANT MONITORING
- MARKET OPPORTUNITIES FOR POSTOPERATIVE MONITORING
- Table 42 : ONE-YEAR ADJUSTED PATIENT SURVIVAL BY ORGAN FOR TRANSPLANTS,
2007
- Table 43 : SELECTED PHARMACEUTICAL PIPELINE FOR ANTI-INFECTIVES FOR
TRANSPLANT RECIPIENTS, 2010
Chapter- 9: ALTERNATIVE DEVICES AND TECHNOLOGIES
- ALTERNATIVES TO CORNEAL TRANSPLANTATION
- ALTERNATIVES TO INTESTINAL TRANSPLANTATION
- ALTERNATIVES TO PANCREAS TRANSPLANTATION
- ALTERNATIVES TO LIVER TRANSPLANTATION
- ALTERNATIVES TO LUNG TRANSPLANTATION
- ALTERNATIVES TO BONE GRAFTS
- ALTERNATIVES TO VASCULAR TRANSPLANTATION
- ALTERNATIVES TO VASCULAR TRANSPLANTATION
- ALTERNATIVES TO SKIN TRANSPLANTATION
- ALTERNATIVES TO HEART TRANSPLANTATION
- ORTHOPEDIC DEVICES FOR TRANSPLANTATION
Chapter- 10: REGULATIONS AND REIMBURSEMENT
- REGULATIONS IN THE U.S.
- REGULATIONS OUTSIDE THE U.S.
- REIMBURSEMENT IN THE U.S.
- REIMBURSEMENT OUTSIDE THE U.S.
Chapter- 11: EMERGING PROCEDURES AND PRODUCTS IN DEVELOPMENT
- MACHINE PERFUSION OF SOLID ORGANS
- ORGAN PRESERVATION SOLUTIONS IN DEVELOPMENT
- REGENERATIVE MEDICINE
- ORGAN REJECTION STRATEGIES
- STEM CELL RESEARCH
- ADVANCES IN CARDIOVASCULAR TREATMENTS
- PHARMACEUTICAL PIPELINE DEVELOPMENT
- Table 58 : PHARMACEUTICAL PIPELINE/DEVICE BY MANUFACTURER, TYPE OF
PRODUCT, INDICATIONS FOR USE, AND STAGE OF CLINICAL TESTING
Chapter- 12: COMPANY DIRECTORY
- ABBOTT LABORATORIES
- ADVANCED BIOHEALING, INC.
- ALLOSOURCE
- ARBIOS SYSTEMS, INC.
- ARTHREX, INC.
- ASTELLAS PHARMA, INC.
- BIOMET, INC
- BIORAD LABORATORIES
- BRISTOL-MYERS SQUIBB
- CELERA CORP.
- CENTACOR ORTHO BIOTECH, LTD.
- CONMED-LINVATEC CORP.
- CRYOLIFE, INC.
- DEPUY ORTHOPEDICS
- DIAGAST
- DR. F. KOHLER CHEMIE GMBH
- EDWARDS LIFESCIENCES
- EXACTECH
- FORTICELL BIOSCIENCE
- GEN-PROBE, INC.
- GENZYME
- W.L. GORE & ASSOCIATES
- HEMOCLEANSE, INC.
- INTEGRA LIFESCIENCE
- INVITROGEN (SEE LIFE TECHNOLOGIES)
- JOHNSON & JOHNSON
- KIADIS PHARMA
- KINETIC CONCEPTS, INC. (KCI)
- LIFEBLOOD MEDICAL, INC.
- LIFECELL CORP. (SEE KINETIC CONCEPTS, INC.)
- LIFECYCLE PHARMA A/S
- LIFE TECHNOLOGIES
- LIVING CELL TECHNOLOGIES, LTD.
- LUMINEX CORP.
- MEDTRONIC, INC.
- NOVARTIS AG
- ONE LAMBDA, INC.
- ON-X LIFE TECHNOLGIES, INC.
- ORGANOGENESIS, INC.
- ORTHO-CLINICAL DIAGNOSTICS
- OSTEOTECH
- PDL BIOPHARMA
- PFIZER, INC.
- PROTEOME SCIENCES, PLC
- ROCHE PHARMACEUTICALS
- RTI BIOLOGICS
- SMITH & NEPHEW, PLC
- SORIN GROUP, S.P.A.
- ST. JUDE MEDICAL
- STRYKER CORP.
- SYNCARDIA SYSTEMS, INC.
- SYNOVIS SURGICAL INNOVATIONS
- SYTHES (NORTH AMERICA)
- TEI BIOSCIENCE
- TEVA PHARMACEUTICALS, LTD.
- TERUMO MEDICAL CORP.
- THORATEC CORP.
- TORNIER, INC. (U.S.)
- TRANSMEDICS, INC.
- VIROPHARMA, INC.
- WORLDHEART CORP.
- WRIGHT MEDICAL TECHNOLOGY, INC.
- WYETH (SEE PFIZER)
- ZIMMER HOLDINGS, INC.
Chapter- 13: APPENDIX
DEFINITIONS
List of Tables
- Summary Table : PROJECTED GLOBAL MARKET FOR TRANSPLANTATION PRODUCTS AND
DEVICES, THROUGH 2015
- Table 1 : TIMELINE OF ORGAN TRANSPLANTATION HISTORY, 1900 - 2010
- Table 2 : SELECTED TRANSPLANT INDUSTRY ACQUISITIONS, 2006 - 2010
- Table 3 : U.S. ORGAN TRANSPLANTS: AVERAGE FIRST YEAR COST, ESTIMATED
NUMBER OF PROCEDURES, AND VALUE BY TYPE OF ORGAN TRANSPLANT, 2008
- Table 4 : NUMBER OF DONATED CADAVERIC ORGANS BY SELECTED REGION, 2004 -
2008
- Table 5 : ADJUSTED U.S. GRAFT SURVIVAL RATES BY ORGAN FOR TRANSPLANTS
PERFORMED, 2000 - 2007
- Table 6 : ADJUSTED U.S. PATIENT SURVIVAL RATES BY ORGAN FOR TRANSPLANTS
PERFORMED, 2000 - 2007
- Table 7 : TISSUE TYPING TECHNOLOGIES
- Table 8 : PROJECTED GLOBAL MARKET FOR TISSUE TYPING, THROUGH 2015
- Table 9 : U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT: ALL
ORGANS, 2003 - 2007*
- Table 10 : RECOVERED ORGANS NOT USED BY TYPE IN U.S., 2003 - 2007
- Table 11 : PRESERVATION TIME FOR TRANSPLANTED ORGANS
- Table 12 : MAJOR ORGAN PRESERVATION SOLUTIONS
- Table 13 : PROJECTED GLOBAL MARKET FOR ORGAN PRESERVATION SOLUTIONS (NOT
INCLUDING THE PAPWORTH COCKTAIL) BY GEOGRAPHIC REGION, THROUGH 2015
- Table 14 : PROJECTED GROWTH IN TISSUE MARKET REVENUES BY REGION, THROUGH
2015
- Table 15 : PROJECTED GLOBAL TISSUE GRAFTING BY TISSUE TYPE, THROUGH 2015
- Table 16 : GLOBAL HEART VALVE MARKET, THROUGH 2015
- Table 17 : LEADING HEART VALVE SUPPLIERS, 2009
- Table 18 : PROJECTED GLOBAL GROWTH OF CORNEAL TRANSPLANT MARKET, THROUGH
2015*
- Table 19 : PROJECTED GLOBAL MARKET FOR BLOOD STEM CELL TRANSPLANTATION,
THROUGH 2015
- Table 20 : PROJECTED GLOBAL HEMATOPOIETIC STEM CELL TRANSPLANT PROCEDURES,
THROUGH 2015
- Table 21 : PROJECTED GLOBAL MARKET FOR ORTHOBIOLOGICAL PRODUCTS, THROUGH
2015
- Table 22 : NUMBER OF BONE MARROW DONORS BY COUNTRY, 2010
- Table 23 : PROJECTED GLOBAL GROWTH OF SKIN AND COLLAGEN TRANSPLANTS,
THROUGH 2015
- Table 24 : PROJECTED GLOBAL VASCULAR TISSUE TRANSPLANTATION MARKET,
THROUGH 2015
- Table 25 : SELECTED COMMERCIAL OPPORTUNITIES IN TISSUE TRANSPLANTATION,
2010
- Table 26 : PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS USED IN
TRANSPLANTS BY TYPE, THROUGH 2015
- Table 27 : IMMUNOSUPPRESSANT DRUGS APPROVED IN THE U.S., THE EU, AND
JAPAN, 2009
- Table 28 : IMMUNOSUPPRESSANTS BY DRUG CLASS, GENERIC NAME, BRAND NAME AND
MANUFACTURER
- Table 29 : GLOBAL MARKET FOR CALCINEURIN INHIBITORS TO TREAT ORGAN
TRANSPLANT REJECTION, THROUGH 2015
- Table 30 : GLOBAL MARKET FOR ANTI-PROLIFERATIVE AGENTS TO TREAT ORGAN
TRANSPLANT REJECTION, THROUGH 2015
- Table 31 : PROJECTED GLOBAL MARKET FOR M-TOR INHIBITORS TO TREAT ORGAN
TRANSPLANT REJECTION, THROUGH 2015
- Table 32 : ANTIBODY PRODUCTS FOR TREATMENT OF ORGAN TRANSPLANT REJECTION
- Table 33 : PROJECTED GLOBAL MARKET FOR MONCLONAL ANTIBODY PRODUCTS,
THROUGH 2015
- Table 34 : PROJECTED GLOBAL MARKET FOR POLYCLONAL ANTIBODY PRODUCTS,
THROUGH 2015
- Table 35 : IMMUNOSUPPRESSANT USE FOR INDUCTION BY ORGAN IN U.S., 2007
- Table 36 : IMMUNOSUPPRESSANT USE FOR MAINTENANCE (UP TO 2 YEARS POST
TRANSPLANT) BY ORGAN, 2006*
- Table 37 : IMMUNOSUPPRESSANT USE FOR REJECTION THERAPY FOLLOWING SOLID
ORGAN TRANSPLANTATION BY ORGAN, 2006*
- Table 38 : SELECTED IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT, 2010
- Table 39 : COMMON ANTI-INFECTIVE AND IMMUNOSUPPRESSANT AGENTS AND
INTERACTIONS, 2009
- Table 40 : POST-TRANSPLANT INFECTIONS BY TYPE OF TRANSPLANT, WITH COMMON
TIME FRAMES FOR INFECTION
- Table 41 : RECOMMENDED POST-TRANSPLANT CARE, 2009
- Table 42 : ONE-YEAR ADJUSTED PATIENT SURVIVAL BY ORGAN FOR TRANSPLANTS,
2007
- Table 43 : SELECTED PHARMACEUTICAL PIPELINE FOR ANTI-INFECTIVES FOR
TRANSPLANT RECIPIENTS, 2010
- Table 44 : PROJECTED GLOBAL MARKET FOR TRANSPLANTATION ALTERNATIVE
DEVICES, THROUGH 2015
- Table 45 : INDICATIONS FOR BIOARTIFICIAL LIVER TRANSPLANTATION
- Table 46 : GLOBAL MARKET FOR ARTIFICIAL HEART DEVICES, THROUGH 2015
- Table 47 : GLOBAL MARKET FOR TOTAL ARTIFICIAL HEARTS, THROUGH 2015
- Table 48 : GLOBAL MARKET FOR VADS, THROUGH 2015
- Table 49 : SELECTED GLOBAL COMMERCIAL OPPORTUNITIES FOR NEW DEVICES IN THE
FUTURE
- Table 50 : PROJECTED GLOBAL MARKET FOR ORTHOPEDIC DEVICES USED IN
TRANSPLANTATION, THROUGH 2015
- Table 51 : PROJECTED GLOBAL MARKET FOR HIP REPLACEMENTS, THROUGH 2015
- Table 52 : PROJECTED GLOBAL MARKET FOR KNEE REPLACEMENTS, THROUGH 2015
- Table 53 : PROJECTED GLOBAL MARKET FOR SPINAL RECONSTRUCTIVE PRODUCTS,
THROUGH 2015
- Table 54 : PROJECTED GLOBAL MARKET FOR EXTREMITY REPAIR/REPLACEMENTS,
THROUGH 2015
- Table 55 : IMMUNOSUPPRESSIVE DRUGS CURRENTLY COVERED BY MEDICARE*
- Table 56 : OVERVIEW OF MEDICARE IMMUNOSUPPRESSIVE DRUG COVERAGE
- Table 57 : TYPES OF REGENERATIVE CELLULAR THERAPIES
- Table 58 : PHARMACEUTICAL PIPELINE/DEVICE BY MANUFACTURER, TYPE OF
PRODUCT, INDICATIONS FOR USE, AND STAGE OF CLINICAL TESTING
List of Figures
- Summary Figure : PROJECTED GLOBAL MARKET SHARES OF TRANSPLANTATION
PRODUCTS AND DEVICES, 2010 AND 2015
- Figure 1 : GLOBAL MARKET SHARES IN TISSUE TYPING TECHNOLOGIES BY MARKET
LEADER, 2010
- Figure 2 : GLOBAL MARKET SHARE OF ORGAN PRESERVATION SOLUTIONS BY
MANUFACTURER, 2009
- Figure 3 : GLOBAL TISSUE MARKET SHARES BY REGION, 2010 AND 2015
- Figure 3 : GLOBAL TISSUE MARKET SHARES BY REGION, 2010 AND 2015
- Figure 4 : GLOBAL MARKET SHARES OF SELECTED MARKET LEADERS IN THE SKIN AND
COLLAGEN TRANSPLANT MARKET, 2009
- Figure 5 : PROJECTED GLOBAL MARKET SHARES OF IMMUNOSUPPRESSIVES BY TYPE,
THROUGH 2015
- Figure 5 : PROJECTED GLOBAL MARKET SHARES OF IMMUNOSUPPRESSIVES BY TYPE,
THROUGH 2015
- Figure 6 : GLOBAL MARKET FOR ORTHOPEDIC DEVICES, 2010 AND 2015
- Figure 6 : GLOBAL MARKET FOR ORTHOPEDIC DEVICES, 2010 AND 2015
- Figure 7 : GLOBAL MARKET SHARES OF THE SPINAL RECONSTRUCTION MARKET BY
COMPANY, 2009
|
